Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor
Comparative study published in The EMBO journal (2000)
Abstract
The serine proteinase alpha-thrombin plays a pivotal role in the regulation of blood fluidity, and therefore constitutes a primary target in the treatment of various haemostatic disorders. Haemadin is a slow tight- binding thrombin inhibitor from the land-living leech Haemadipsa sylvestris. Here we present the 3.1 A crystal structure of the human alpha-thrombin- haemadin complex. The N-terminal segment of haemadin binds to the active site of thrombin, forming a parallel beta-strand with residues Ser214-Gly216 of the proteinase. This mode of binding is similar to that observed in another leech-derived inhibitor, hirudin. In contrast to hirudin, however, the markedly acidic C-terminal peptide of haemadin does not bind the fibrinogen-recognition exosite, but interacts with the heparin-binding exosite of thrombin. Thus, haemadin binds to thrombin according to a novel mechanism, despite an overall structural similarity with hirudin. Haemadin inhibits both free and thrombomodulin-bound alpha-thrombin, but not intermediate activation forms such as meizothrombin. This specific anticoagulant ability of haemadin makes it an ideal candidate for an antithrombotic agent, as well as a starting point for the design of novel antithrombotics.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
The serine proteinase alpha-thrombin plays a pivotal role in the regulation of blood fluidity, and therefore constitutes a primary target in the treatment of various haemostatic disorders.
Why This Matters for Hirudotherapy
Using X-ray crystallography, this study resolved the 3.1 Angstrom structure of human alpha-thrombin bound to haemadin, a tight-binding thrombin inhibitor from the land leech Haemadipsa sylvestris, showing that its N-terminus blocks thrombin's active site like hirudin but its acidic C-terminus uniquely engages the heparin-binding exosite (exosite II) rather than the fibrinogen-recognition exosite that hirudin uses. It reports that haemadin inhibits both free and thrombomodulin-bound thrombin but not meizothrombin, which the authors note makes it a candidate antithrombotic and a template for designing new agents. This matters to the leech-secretome drug-discovery narrative because it documents a second leech anticoagulant with a distinct, well-defined molecular mechanism, illustrating the pharmacological diversity of leech-derived thrombin inhibitors. As a structural and biochemical study, it characterizes a single molecule's binding mode and does not by itself establish clinical efficacy or safety in patients.
Citation
Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor
Richardson JL et al. · The EMBO journal, 2000
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026